A microRNA-based endometrial receptivity test to identify a patient’s optimal window of implantation
WHY CHOOSE MIRA™?
MIRA™ uses a less invasive biopsy procedure and reduces the margin of error through the utilization of microRNA (miRNA), a more stable and tolerant genetic material than messenger RNA (mRNA). This unique endometrial receptivity analysis test delivers fast and reliable results using novel miRNA biomarkers to increase the IVF pregnancy rate to 70% among patients who have a history of implantation failure.
MIRA™ provides actionable results in over 99% of first biopsies, so patients and healthcare providers can be confident that they’re getting the information they need in a timely manner.
MIRA™ can process smaller quantities and lower-quality tissue samples, meaning a less uncomfortable biopsy procedure for patients.
MIRA™’s 100 miRNA biomarkers target over 600 endometrial receptivity-related genes to accurately identify the optimal time for embryo transfer.
HOW DOES MIRA™ HELP HEALTH CARE PROFESSIONALS?
We support healthcare professionals worldwide in their efforts to deliver fast and reliable results. Our solution provides valuable insight during the IVF treatment cycle to ensure the best care possible for patients.Learn How
HOW CAN FAMILIES USE MIRA™ IN THEIR FERTILITY JOURNEY?
We work to stay at the forefront of the issues families face when undergoing IVF. We partner with local healthcare professionals and service providers to provide the best solutions to patients.Learn How
INTI LABS’ SOLUTION
Inti’s pioneering miRNA-based endometrial receptivity test is used during the pre-implantation stage of in vitro fertilization (IVF) to enhance and personalize a patient’s treatment.
IMPROVING IVF SUCCESS
Inti Labs continues to progress the IVF landscape for both healthcare professionals and families undergoing treatment. We seek to empower them to make informed decisions through precise and personalized miRNA-based testing.
ASSISTING HEALTHCARE PROVIDERS
By improving the embryo transfer process, we provide the best genetic solutions to support healthcare professionals as they guide patients through the treatment process.
REFINING THE FERTILITY JOURNEY
We collaborate with clinics, hospitals, service providers, and distributors to bring solutions to healthcare professionals and patients worldwide. Our solutions provide valuable insight during the IVF treatment cycle to ensure the best care possible for patients.
WHAT IS MIRA™?
MIRA™ is a miRNA-based endometrial receptivity test that helps healthcare providers determine a patient’s window of implantation for optimized embryo transfer. It does this by assessing a combination of miRNA biomarkers to find the status of a patient’s endometrium receptivity, which can increase the chances of successful IVF treatment.
WHAT IS ENDOMETRIAL RECEPTIVITY?
Endometrial receptivity refers to the status of the endometrium in relation to its ability to accept an embryo for implantation. There is a window of 2 to 3 days around the middle of your menstrual cycle, when the mucus membrane lining the uterus, the endometrium, is at the ideal thickness and consistency for embryo implantation to happen. This interval of receptivity is commonly called the window of implantation (WOI).
WHAT IS THE WINDOW OF IMPLANTATION (WOI)?
The interval of receptivity, also known as the window of implantation, typically occurs between days 19 and 21 of the menstrual cycle of fertile women. Large-scale studies show that 30% of infertility patients have a displaced WOI. One of the main causes of implantation failure is the lack of synchronization between the embryo and endometrium.
WHAT IS IN VITRO FERTILIZATION (IVF)?
In vitro fertilization is a form of assisted reproductive technology where an egg is fertilized with sperm in a laboratory environment. Through a combination of medication and surgical procedures, eggs are retrieved, fertilized, and implanted for reproduction. A typical cycle of IVF takes 2 to 3 weeks.